Erratum: Guidelines for the diagnosis and management of gastroesophageal reflux disease (American Journal of Gastroenterology (2013) 108 (308-328) DOI: 10.1038/ajg.2012.444);Guidelines for the diagnosis and management of gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 108, Issue 3, 2013, Pages 308-328

  Katz, Philip O ^a   Gerson, Lauren B ^b   Vela, Marcelo F ^c  

^a EINSTEIN MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BICARBONATE PLUS OMEPRAZOLE; CLOPIDOGREL; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADD ON THERAPY; AGITATION; ARTICLE; ASTHMA; BARRETT ESOPHAGUS; BEDTIME DOSAGE; CHRONIC COUGH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; DEPRESSION; DROWSINESS; DYSTONIA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; IRRITABILITY; LARYNGITIS; LIFESTYLE MODIFICATION; MEDICAL DOCUMENTATION; NONCARDIAC CHEST PAIN; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RISK FACTOR; ROUX Y ANASTOMOSIS; SIDE EFFECT; STOMACH FUNDOPLICATION; TARDIVE DYSKINESIA;

EID: 84875225548     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.314     Document Type: Erratum

References (184)

1. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-4.
2. Atkins D, Briss PA, Eccles M et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5: 25-36.
3. Vakil N, van Zanten SV, Kahrilas P et al. The Montreal defi nition and classifi cation of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
4. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
5. Kahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
6. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
7. Camilleri M, Dubois D, Coulie B et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 543-52.
8. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2: 665-8.
9. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol 2011; 9: 824-33.
10. Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 618-27.
11. Gerson LB, Fass R. A systematic review of the defi nitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 372-8.
12. Becher A, Dent J. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis. Aliment Pharmacol Ther 2011; 33: 442-54.
13. Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004; 126: 660-4.
14. Rubenstein JH, Scheiman JM, Sadeghi S et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011; 106: 254-60.
15. Lin M, Gerson LB, Lascar R et al. Features of gastroesophageal reflux disease in women. Am J Gastroenterol 2004; 99: 1442-7.
16. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 2619-28.
17. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
18. Labenz J, Jaspersen D, Kulig M et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004; 99: 1652-6.
19. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-90.
20. Moayyedi P, Talley NJ, Fennerty MB et al. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295: 1566-76.
21. Numans ME, Lau J, de Wit NJ et al. Short-term treatment with protonpump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-27.
22. Cremonini F, Wise J, Moayyedi P et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100: 1226-32.
23. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60: 1473-8.
24. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102: 668-85.
25. Johnston BT, Troshinsky MB, Castell JA et al. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1181-5.
26. Richter JE, Castell DO. Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy. Ann Intern Med 1982; 97: 93-103.
27. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classifi cation. Gut 1999; 45: 172-80.
28. Johnsson F, Joelsson B, Gudmundsson K et al. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714-8.
29. Gerson LB, Boparai V, Ullah N et al. Oesophageal and gastric pH profi les in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637-43.
30. Frazzoni M, Savarino E, Manno M et al. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 30: 508-15.
31. Appelmelk BJ, Simoons-Smit I, Negrini R et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 1996; 64: 2031-40.
32. Knuff TE, Benjamin SB, Worsham GF et al. Histologic evaluation of chronic gastroesophageal reflux. An evaluation of biopsy methods and diagnostic criteria. Dig Dis Sci 1984; 29: 194-201.
33. Schindlbeck NE, Wiebecke B, Klauser AG et al. Diagnostic value of histology in non-erosive gastro-oesophageal reflux disease. Gut 1996; 39: 151-4.
34. Takubo K, Honma N, Aryal G et al. Is there a set of histologic changes that are invariably reflux associated? Arch Pathol Lab Med 2005; 129: 159-63.
35. Sifrim D, Castell D, Dent J et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and defi nitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
36. Connor J, Richter J. Increasing yield also increases false positives and best serves to exclude GERD. Am J Gastroenterol 2006; 101: 460-3.
37. Yaghoobi M, Farrokhyar F, Yuan Y et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007-13.
38. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
39. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
40. Olans LB, Wolf JL. Gastroesophageal reflux in pregnancy. Gastrointest Endosc Clin N Am 1994; 4: 699-712.
41. Marrero JM, Goggin PM, de Caestecker JS et al. Determinants of pregnancy heartburn. Br J Obstet Gynaecol 1992; 99: 731-4.
42. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005; 22: 749-57.
43. Rey E, Rodriguez-Artalejo F, Herraiz MA et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol 2007; 102: 2395-400.
44. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965-71.
45. Johnson T, Gerson L, Hershcovici T et al. Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 31: 607-14.
46. Jacobson BC, Somers SC, Fuchs CS et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 2340-8.
47. Fraser-Moodie CA, Norton B, Gornall C et al. Weight loss has an independent benefi cial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 1999; 34: 337-40.
48. Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol 1996; 8: 635-40.
49. Gagne DJ, Dovec E, Urbandt JE. Laparoscopic revision of vertical banded gastroplasty to Roux-en-Y gastric bypass: outcomes of 105 patients. Surg Obes Relat Dis 2011; 7: 493-9.
50. Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion 1977; 15: 104-9.
51. Hamilton JW, Boisen RJ, Yamamoto DT et al. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci 1988; 33: 518-22.
52. Pollmann H, Zillessen E, Pohl J et al. Effect of elevated head position in bed in therapy of gastroesophageal reflux. Z Gastroenterol 1996; 34 (Suppl 2): 93-9.
53. Cremonini F, Ziogas DC, Chang HY et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 29-42.
54. Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol 2005; 11: 4291-9.
55. Chiba N, De Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
56. Robinson M, Sahba B, Avner D et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995; 9: 25-31.
57. Vantrappen G, Rutgeerts L, Schurmans P et al. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523-9.
58. van Pinxteren B, Sigterman KE, Bonis P et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev-CD002095.
59. Gralnek IM, Dulai GS, Fennerty MB et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006; 4: 1452-8.
60. Gerson LB, Mitra S, Bleker WF et al. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy. Aliment Pharmacol Ther 2012; 35: 803-9.
61. Metz DC, Vakily M, Dixit T et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 29: 928-37.
62. Sharma P, Shaheen NJ, Perez MC et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731-41.
63. Dickman R, Boaz M, Aizic S et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011; 17: 387-94.
64. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
65. Lee RD, Mulford D, Wu J et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing fl exibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther 2010; 31: 1001-11.
66. Gunaratnam NT, Jessup TP, Inadomi J et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473-7.
67. Fass R, Sontag SJ, Traxler B et al. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4: 50-6.
68. Schindlbeck NE, Klauser AG, Berghammer G et al. Th ree year follow up of patients with gastrooesophageal reflux disease. Gut 1992; 33: 1016-9.
69. Vigneri S, Termini R, Leandro G et al. A comparison of fi ve maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
70. El-Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.
71. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
72. Pace F, Tonini M, Pallotta S et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 2007; 26: 195-204.
73. Inadomi JM, Jamal R, Murata GH et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095-100.
74. Fackler WK, Ours TM, Vaezi MF et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
75. Champion MC. Prokinetic therapy in gastroesophageal reflux disease. Can J Gastroenterol 1997; 11 (Suppl B): 55B-65B.
76. Richter JE, Sabesin SM, Kogut DG et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1766-72.
77. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31: 11-9.
78. Maddern GJ, Kiroff GK, Leppard PI et al. Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol 1986; 8: 135-40.
79. van Noord C, Dieleman JP, van Herpen G et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010; 33: 1003-14.
80. Grossi L, Spezzaferro M, Sacco LF et al. Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterol Motil 2008; 20: 760-6.
81. Koek GH, Sifrim D, Lerut T et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
82. Vela MF, Tutuian R, Katz PO et al. Baclofen decreases acid and nonacid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-51.
83. Orr WC, Goodrich S, Wright S et al. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil 2012; 24: 553-9.
84. Cange L, Johnsson E, Rydholm H et al. Baclofen-mediated gastrooesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002; 16: 869-73.
85. del Genio G, Tolone S, del Genio F et al. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 2008; 12: 1491-6.
86. Oelschlager BK, Quiroga E, Parra JD et al. Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol 2008; 103: 280-7.
87. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8.
88. Lundell L, Miettinen P, Myrvold HE et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009; 7: 1292-8.
89. Ramos RF, Lustosa SA, Almeida CA et al. Surgical treatment of gastroesophageal reflux disease: total or partial fundoplication? systematic review and meta-analysis. Arq Gastroenterol 2011; 48: 252-60.
90. Wileman SM, McCann S, Grant AM et al. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2010, CD003243.
91. Spechler SJ, Gordon DW, Cohen J et al. The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Am J Gastroenterol 1995; 90: 915-8.
92. Larrain A, Carrasco E, Galleguillos F et al. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 1330-5.
93. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003, CD001496.
94. Swoger J, Ponsky J, Hicks DM et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006; 4: 433-41.
95. De Groot NL, Burgerhart JS, Van De Meeberg PC et al. Systematic review: the effects of conservative and surgical treatment for obesity on gastrooesophageal reflux disease. Aliment Pharmacol Ther 2009; 30: 1091-102.
96. Urbach DR, Horvath KD, Baxter NN et al. A research agenda for gastrointestinal and endoscopic surgery. Surg Endosc 2007; 21: 1518-25.
97. Testoni PA, Vailati C, Testoni S et al. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings aff ecting outcome. Surg Endosc 2012; 26: 1425-35.
98. Witteman BP, Strijkers R, de Vries E et al. Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice. Surg Endosc 2012; 26: 3307-15.
99. Lipham JC, Demeester TR, Ganz RA et al. The LINX((R)) reflux management system: confi rmed safety and efficacy now at 4 years. Surg Endosc 2012; 26: 2944-9.
100. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 931-50.
101. Lodato F, Azzaroli F, Turco L et al. Adverse effects of proton pump inhibitors . Best Pract Res Clin Gastroenterol 2010; 24: 193-201.
102. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-81.
103. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-9.
104. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165-77.
105. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337-44.
106. Hermos JA, Young MM, Fonda JR et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012; 54: 33-42.
107. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
108. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine- 2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93-101.
109. Kwok CS, Nijjar RS, Loke YK. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf 2011; 34: 47-57.
110. Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209-18.
111. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
112. Furuta T, Iwaki T, Umemura K. Influences of diff erent proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70: 383-92.
113. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
114. Wu CY, Chan FK, Wu MS et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010; 139: 1165-71.
115. Evanchan J, Donnally MR, Binkley P et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol 2010; 33: 168-71.
116. Tentzeris I, Jarai R, Farhan S et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010; 104: 1211-8.
117. Ray WA, Murray KT, Griffi n MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-45.
118. Bhatt DL, Cryer BL, Contant CF et al.. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
119. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
120. Gerson LB, McMahon D, Olkin I et al. Lack of signifi cant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci 2012; 57: 1304-13.
121. Kwok CS, Jeevanantham V, Dawn B et al. No consistent evidence of diff erential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 2013 (in-press).
122. Chen M, Wei JF, Xu YN et al. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther 2012; 30: e227-33.
123. Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut 2007; 56: 1654-64.
124. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141: 640-7.
125. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755-60.
126. Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85.
127. Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc 2009; 69: 917-30.
128. Smith J, Woodcock A, Houghton L. New developments in refluxassociated cough. Lung 2010; 188 (Suppl 1): S81-6.
129. Abou-Ismail A, Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. Curr Gastroenterol Rep 2011; 13: 213-8.
130. Wiener GJ, Richter JE, Copper JB et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988; 83: 358-61.
131. Weusten BL, Roelofs JM, Akkermans LM et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994; 107: 1741-5.
132. Francis DO, Goutte M, Slaughter JC et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. Laryngoscope 2011; 121: 1902-9.
133. Smith JA, Decalmer S, Kelsall A et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 2010; 139: 754-62.
134. Vaezi MF, Hicks DM, Abelson TI et al. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 2003; 1: 333-44.
135. Milstein CF, Charbel S, Hicks DM et al. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). Laryngoscope 2005; 115: 2256-61.
136. Branski RC, Bhattacharyya N, Shapiro J. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope 2002; 112: 1019-24.
137. Kiljander TO, Junghard O, Beckman O et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181: 1042-8.
138. Harding SM, Sontag SJ. Asthma and gastroesophageal reflux. Am J Gastroenterol 2000; 95: S23-32.
139. Chan WW, Chiou E, Obstein KL et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med 2011; 171: 620-9.
140. Chang AB, Lasserson TJ, Gaffney J et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011, CD004823.
141. Qadeer MA, Phillips CO, Lopez AR et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 2646-54.
142. Ip S, Chung M, Moorthy D et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease: Update Agency for Healthcare Research and Quality. Rockville, MD, 2011.
143. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med 1994; 96: 321-6.
144. Harding SM, Richter JE, Guzzo MR et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100: 395-405.
145. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10: 252-7.
146. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
147. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
148. El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol 2009; 104: 2161-7.
149. Hatlebakk JG, Katz PO, Castell DO. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 847-60.
150. Barrison AF, Jarboe LA, Weinberg BM et al. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001; 111: 469-73.
151. Fass R, Murthy U, Hayden CW et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595-603.
152. Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol 2011; 106: 1439-45.
153. Vela MF, Camacho-Lobato L, Srinivasan R et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 15996-06.
154. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 283-9.
155. Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
156. Roman S, Bruley des Varannes S, Pouderoux P et al. Ambulatory 24-h oesophageal impedance-pH recordings: reliability of automatic analysis for gastro-oesophageal reflux assessment. Neurogastroenterol Motil 2006; 18: 978-86.
157. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-43.
158. Hemmink GJ, Bredenoord AJ, Weusten BL et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on'or 'off'proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-53.
159. Pritchett JM, Aslam M, Slaughter JC et al. Effi cacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7: 743-8.
160. Gawron AJ, Rothe J, Fought AJ et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol 2012; 10: 620-5.
161. Mainie I, Tutuian R, Agrawal A et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastrooesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93: 1483-7.
162. Frazzoni M, Conigliaro R, Melotti G. Reflux parameters as modifi ed by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy: a study using impedance-pH monitoring. Dig Dis Sci 2011; 56: 1099-106.
163. El-Serag HB, Kvapil P, Hacken-Bitar J et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005; 100: 2151-6.
164. Bytzer P, Havelund T, Hansen JM. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 1993; 28: 119-25.
165. Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
166. Modiano N, Gerson LB. Risk factors for the detection of Barrett's esophagus in patients with erosive esophagitis. Gastrointest Endosc 2009; 69: 1014-20.
167. Hanna S, Rastogi A, Weston AP et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006; 101: 1416-20.
168. Stoltey J, Reeba H, Ullah N et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2007; 25: 83-91.
169. Ruigomez A, Garcia Rodriguez LA, Wallander MA et al. Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol 2006; 101: 2685-92.
170. Wang A, Mattek NC, Holub JL et al. Prevalence of complicated gastroesophageal reflux disease and Barrett's esophagus among racial groups in a multi-center consortium. Dig Dis Sci 2009; 54: 964-71.
171. Marks RD, Richter JE, Rizzo J et al. Omeprazole vs H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15.
172. Smith PM, Kerr GD, Cockel R et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994; 107: 1312-8.
173. Ramage Jr JI, Rumalla A, Baron TH et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol 2005; 100: 2419-25.
174. Altintas E, Kacar S, Tunc B et al. Intralesional steroid injection in benign esophageal strictures resistant to bougie dilation. J Gastroenterol Hepatol 2004; 19: 1388-91.
175. Sgouros SN, Vlachogiannakos J, Karamanolis G et al. Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. Am J Gastroenterol 2005; 100: 1929-34.
176. Westhoff B, Brotze S, Weston A et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005; 61: 226-31.
177. Falk GW, Th ota PN, Richter JE et al. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. Clin Gastroenterol Hepatol 2005; 3: 1089-94.
178. Guardino JM, Khandwala F, Lopez R et al. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006; 101: 2187-93.
179. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis,
180. Duroux P, Bauerfeind P, Emde C et al. Early dinner reduces nocturnal gastric acidity. Gut 1989; 30: 1063-7.
181. Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther 1998; 12: 1033-8.
182. Schindlbeck NE, Heinrich C, Dendorfer A et al. Influence of smoking and esophageal intubation on esophageal pH-metry. Gastroenterology 1987; 92: 1994-7.
183. Waring JP, Eastwood TF, Austin JM et al. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol 1989; 84: 1076-8.
184. Kadakia SC, Kikendall JW, Maydonovitch C et al. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol 1995; 90: 1785-90.